<H1>Chapter DOI: 10.1007/978-1-60327-829-4_11<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>35</td></tr><tr><td>Springer references</td><td>6</td></tr><tr><td>Non Springer references</td><td>29</td></tr><tr><td>BibStructured Count</td><td width="10%">31</td></tr><tr><td>BibUnstructured Count</td><td width="10%">4</td></tr><tr><td>DOI already available in SpringerLink</td><td>16</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>1</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>1</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>1</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_11</td><td>BibArticle</td><td>White RJ, Durr FE. Development of mitoxantrone. Invest New Drugs 1985;3:85&#8211;93.</td><td><a href=http://dx.doi.org/10.1007/BF00174154>10.1007/BF00174154</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2_11</td><td>BibArticle</td><td>Paciucci PA, Dutcher JP, Cuttner J, Strauman JJ, Wiernik PH, Holland JF. Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia. Leukemia 1987;1:565&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR3_11</td><td>BibArticle</td><td>Spadea A, Petti MC, Fazi P et al. Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia. Leukemia 1993;7:549&#8211;52.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4_11</td><td>BibUnstructured</td><td>U.S. Food and Drug Administration Center for Drug Evaluation and Research Approval Summary for Mitoxantrone. (Accessed May 6, <span style='background:#66FF66'>2008</span>, at <span style='background:#FF3300'>www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=91</span>).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5_11</td><td>BibArticle</td><td>Lown JW, Hanstock CC, Bradley RD, Scraba DG. Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy. Mol Pharmacol 1984;25:178&#8211;84.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6_11</td><td>BibArticle</td><td>Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984;226:466&#8211;8.</td><td><a href=http://dx.doi.org/10.1126/science.6093249>10.1126/science.6093249</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_11</td><td>BibArticle</td><td>Ehninger G, Proksch B, Heinzel G, Schiller E, Weible KH, Woodward DL. The pharmacokinetics and metabolism of mitoxantrone in man. Invest New Drugs 1985;3:109&#8211;16.</td><td><a href=http://dx.doi.org/10.1007/BF00174157>10.1007/BF00174157</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8_11</td><td>BibUnstructured</td><td>Mitoxantrone. In: Micromedex Healthcare Series: Thomson Health Care; <span style='background:#66FF66'>2008</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR9_11</td><td>BibArticle</td><td>Alberts DS, Peng YM, Bowden GT, Dalton WS, Mackel C. Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 1985;3:101&#8211;7.</td><td><a href=http://dx.doi.org/10.1007/BF00174156>10.1007/BF00174156</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, VolumeID, Year, Author_FamilyName_2, ArticleTitle, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR10_11</td><td>BibArticle</td><td>Van Belle SJ, de Planque MM, Smith IE et al. Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. Cancer Chemother Pharmacol 1986;18:27&#8211;32.</td><td><a href=http://dx.doi.org/10.1007/BF00253059>10.1007/BF00253059</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_11</td><td>BibArticle</td><td>Savaraj N, Lu K, Manuel V, Loo TL. Pharmacology of mitoxantrone in cancer patients. Cancer Chemother Pharmacol 1982;8:113&#8211;7.</td><td><a href=http://dx.doi.org/10.1007/BF00292881>10.1007/BF00292881</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_11</td><td>BibArticle</td><td>Rosenbaum EH, Cohen RA, Glatstein HR. Vaccination of a patient receiving immunosuppressive therapy for lymphosarcoma. JAMA 1966;198:737&#8211;40.</td><td><a href=http://dx.doi.org/10.1001/jama.1966.03110200093025>10.1001/jama.1966.03110200093025</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_11</td><td>BibArticle</td><td>Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:1&#8211;48.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14_11</td><td>BibBook</td><td>Lacy CF ed. Drug Information Handbook. 16 ed. Hudson, OH: Lexi-Comp. 2008.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR15_11</td><td>BibArticle</td><td>Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K. Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 1985;3:123&#8211;32.</td><td><a href=http://dx.doi.org/10.1007/BF00174159>10.1007/BF00174159</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_11</td><td>BibUnstructured</td><td>ISMP&#8217;s List of High Alert Medications. <span style='background:#66FF66'>2008</span>. (Accessed June 13, 2008, at <span style='background:#FF3300'>http://www.ismp.org/Tools/highalertmedications.pdf</span>.)</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17_11</td><td>BibUnstructured</td><td>Novantrone (mitoxantrone) Package Insert. In. Melville, <span style='background:#C0FFC0'>NY</span>: OSI Oncology; <span style='background:#66FF66'>2008</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR18_11</td><td>BibArticle</td><td>Flaig TW, Tangen CM, Hussain MH et al. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 2008;26:1532&#8211;6.</td><td><a href=http://dx.doi.org/10.1200/JCO.2007.13.4197>10.1200/JCO.2007.13.4197</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19_11</td><td>BibArticle</td><td>Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994;83:2780&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR20_11</td><td>BibArticle</td><td>Pedersen-Bjergaard J, Andersen MK, Johansson B. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors. J Clin Oncol 1998;16:1897&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21_11</td><td>BibArticle</td><td>Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756&#8211;64.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR22_11</td><td>BibArticle</td><td>Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506&#8211;13.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR23_11</td><td>BibArticle</td><td>Coleman RE, Maisey MN, Knight RK, Rubens RD. Mitoxantrone in advanced breast cancer &#8211; a phase II study with special attention to cardiotoxicity. Eur J Cancer Clin Oncol 1984;20:771&#8211;6.</td><td><a href=http://dx.doi.org/10.1016/0277-5379(84)90215-3>10.1016/0277-5379(84)90215-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_11</td><td>BibArticle</td><td>Stuart-Harris R, Pearson M, Smith IE, Olsen EG. Cardiotoxicity associated with mitoxantrone. Lancet 1984;2:219&#8211;20.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(84)90498-7>10.1016/S0140-6736(84)90498-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_11</td><td>BibArticle</td><td>Savaraj N, Lu K, Valdivieso M et al. Clinical kinetics of 1,4-dihydroxy-5,8-bis [(2-[(2-hydroxyethyl) amino] ethyl] amino-9, 10-anthracenedione. Clin Pharmacol Ther 1982;31:312&#8211;6.</td><td><a href=http://dx.doi.org/10.1038/clpt.1982.39>10.1038/clpt.1982.39</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26_11</td><td>BibArticle</td><td>Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502&#8211;12.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa040720>10.1056/NEJMoa040720</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_11</td><td>BibArticle</td><td>Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513&#8211;20.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa041318>10.1056/NEJMoa041318</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_11</td><td>BibArticle</td><td>Hussain M, Petrylak D, Fisher E, Tangen C, Crawford D. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Semin Oncol 1999;26:55&#8211;60.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR29_11</td><td>BibChapter</td><td>Kolesar J. Oncology pharmacy preparatory review course &#8211; prostate cancer In: Pharmacy ACoC, editor. Oncology Pharmacy Preparatory Review Course; 2006; Fort Lauderdale, Florida: American College of Clinical Pharmacy; 2006. p. 203&#8211;22.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR30_11</td><td>BibArticle</td><td>Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242&#8211;5.</td><td><a href=http://dx.doi.org/10.1200/JCO.2007.12.4008>10.1200/JCO.2007.12.4008</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31_11</td><td>BibArticle</td><td>Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999;17:1654&#8211;63.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR32_11</td><td>BibArticle</td><td>Rosenberg JE, Weinberg VK, Kelly WK et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110:556&#8211;63.</td><td><a href=http://dx.doi.org/10.1002/cncr.22811>10.1002/cncr.22811</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33_11</td><td>BibArticle</td><td>Garmey EG, Sartor O, Halabi S, Vogelzang NJ. Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol 2008;6:118&#8211;22, 27&#8211;32.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR34_11</td><td>BibArticle</td><td>Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer 2006;106:1041&#8211;6.</td><td><a href=http://dx.doi.org/10.1002/cncr.21695>10.1002/cncr.21695</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35_11</td><td>BibArticle</td><td>Hart L, Ciuleanu T, Hainsworth J et al. Randomized Phase 11 Trial of irofulven (IROF)/prednisone(P), IROF/Capecitabine(C)/P or mitoxantrone (M)/P in docetaxel pre-treated hormone refractory prostate cancer (HRPC) patients. J clin Oncol 2006;24(18S pt):Abstract 14513.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>